Update: Video interview with Dr. Baudhuin has been added. In the May issue of “Clinical Chemistry,” Dr. Linnea Baudhuin assesses the recent Food and Drug Administration’s order to 23andMe to cease its marketing of its Personal Genome Service (PGS) test.
The April issue of Clinical Lab Products features Raouf Nakhleh, M.D., a pathologist at the Mayo Clinic in Jacksonville, Fla., and his leadership of CAP’s CDC project to improve the impact of laboratory practice guidelines.
In the March issue of Science, Mayo Clinic’s Fergus Couch, Ph.D., was recognized for his participation in the article, “Two Decades After BRCA: Setting Paradigms in Personalized Cancer Care and Prevention.”
The February issue of Transfusion Journal, features James Stubbs’, M.D., Chair of the Mayo Clinic Division of Transfusion Medicine, article, “Wrapping our arms around the cost of transfusion therapy.”
Mayo Clinic and Mayo Medical Laboratories have signed a collaboration agreement with bioTheranostics to offer CancerTYPE ID® molecular cancer classification test, as part of its surgical pathology consultations, to aid in the management of patients with metastatic cancer.
A clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital indicates that a new drug can often prevent a common, sometimes severe viral disease in patients receiving a transplant of donated blood-making stem cells. In a paper in the Sept. 26 issue of the New England Journal of Medicine, the researchers report that patients who took the drug CMX001 shortly after transplant were far less likely to develop cytomegalovirus (CMV) infection than were patients who took a placebo.
Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years. Working in collaboration with colleagues at Princess Margaret Cancer Centre in Toronto, researchers from Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix were part of the team that conducted the study published in the Sept. 9 issue of “Cancer Cell.”
The summer solstice was Friday, June 21, marking the longest day of the year and the first official day of summer. As the northern hemisphere tilted closest toward the sun, a new UC Irvine/Mayo Clinic Study for the first time in data from the United States finds that vitamin D levels in the population peak in August and are at their lowest in February. This essential vitamin—necessary for healthy bones—is made in the skin upon exposure to ultraviolet B (UVB) rays from the sun.
In the United States, major tick-borne diseases include Lyme disease, anaplasmosis, babesiosis, ehrlichiosis, and Rocky Mountain spotted fever. Historically, only certain pockets of the United States posed a risk for tick-borne disease. However, the geographic range of ticks has expanded and large areas of the population are now at risk. Because of this increased risk, it is important that physicians recognize who to test, when to test, and what test to use.
Routine CT scans – part of the standard of care for patients with diffuse large B cell lymphoma after treatment with immunochemotherapy – may be unnecessary, Mayo Clinic’s Carrie Thompson, M.D., reported at ASCO.
Mayo Clinic and Cancer Genetics Inc. today launched OncoSpire Genomics, a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing. OncoSpire will focus on mutually identified projects in the Biomarker Discovery Program within Mayo’s Center for Individualized Medicine. Mayo Medical Laboratories and Mayo Clinic’s Department of Laboratory Medicine and Pathology will work with Mayo’s Center for Individualized Medicine to help bring discoveries from the joint venture to patients at Mayo Clinic and elsewhere.
In this video, Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., discusses a recent article published in Alimentary Pharmacology & Therapeutics that examined the effectiveness of larazotide acetate as an alternative treatment for celiac disease.